Gastroenterology: Medicine & Research ((GMR) ISSN : 2637-7632, Impact Factor : 0.668)

Safety of Everolimus in Living Donor Liver Transplantation Recipients with Severe Renal Dysfunction with Low Estimated Glomerular Filtration Rate: Can Everolimus Help in Renal Recovery? - Crimson Publishers

 

Safety of Everolimus in Living Donor Liver Transplantation Recipients with Severe Renal Dysfunction with Low Estimated Glomerular Filtration Rate: Can Everolimus Help in Renal Recovery? by Long-Bin Jeng in Gastroenterology Medicine & Research

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Switching from calcineurin inhibitors (CNIs) to non-nephrotoxic mammalian target of rapamycine inhibitors (mTORi) such as everolimus (EVR) can improve renal function in these patients. Single center prospective study by Castroagudin et al. [1] has shown an improvement of renal function after addition of the EVR to primary immunosuppression and reducing the CNIs [1]. The conclusion of the recently conducted global clinical randomized trial H23O4 involving the EVR was that the introduction of EVR with tacrolimus (TAC) reduction from day 30 after liver transplantation achieved a superior renal function with no compromise in efficacy at 12 months after liver transplantation. 

https://crimsonpublishers.com/gmr/fulltext/GMR.000505.php